Blue Jet Healthcare Limited held an earnings conference call for analysts and investors to discuss the financial results for the quarter ended June 30, 2026 (Q1 FY27).

The event was an earnings call held on August 03, 2026. The stated purpose was to discuss the Q1 FY27 financial results and provide a business update.

Management participants from the company included:

  • Mr. Shiven Arora – Managing Director
  • Mr. V.K. Singh – Chief Operating Officer
  • Mr. Ganesh Karuppannan – Chief Financial Officer
  • Mr. Sanjay Sinha – Deputy Chief Financial Officer

The call was moderated by Mr. Advait Bhadekar from Ernst & Young.

The company confirmed that the investor presentation and financial results were available on the company's website and the stock exchanges. The audio transcript and recording of the conference call were also stated to be made available on the company website and the exchanges. The audio was declared corporate material of Blue Jet Healthcare Limited that cannot be copied or rebroadcasted without written consent.

No specific disclaimer regarding the sharing of unpublished price sensitive information (UPSI) was mentioned in the provided transcript.

Financial Highlights Discussed

  • Revenue from operations for Q1 FY27 was reported at INR 293 crores, representing a 25% increase over the previous quarter (Q4 FY26).
  • EBITDA was reported at INR 98 crores, with an EBITDA margin of 33.5% (up from 30.4% in Q4 FY26).
  • Profit After Tax (PAT) margin was 26.7%, a reduction of 0.7% from the previous quarter.
  • Gross margin was reported at 53%, a reduction of 3% from the previous quarter, attributed to raw material price increases and product mix.
  • Growth was primarily driven by a stronger performance in the PI (Pharmaceutical Intermediates) and API vertical, following the normalization of customer inventory.
  • Contrast Media segment revenues declined sequentially due to approximately INR 30 crores of goods in transit at quarter-end, caused by logistical delays (non-availability of containers, longer transit times from geopolitical situations). This revenue is expected to be recognized in Q2 FY27.
  • The company cited significant raw material price increases across the board since March 2026, linked to the geopolitical situation, creating future uncertainty.

Strategic and Operational Updates

  • Vizag Project: Execution activities have commenced with key statutory approvals in place. Phase 1 represents an investment of approximately INR 1,000 crores over the next 3 years. It will focus on contrast media expansion, a multipurpose finishing block, a new high-intensity sweetener, and a multipurpose intermediate cluster. The facility is designed for flexibility across chemistry platforms, including high-potency and peptide manufacturing.
  • Hyderabad R&D Center: Expected to become operational in August 2026. It is designed to strengthen CDMO capabilities in peptides, GLP-1 intermediates, biocatalysts, continuous manufacturing, and complex synthetic pathways. Key scientific talent has been onboarded.
  • Mahad (Unit 3) Backward Integration: Progressing ahead of schedule, with commercial contribution expected in H2 FY27. Approximately INR 210 crores has been invested, with a further INR 40 crores committed. This project aims to vertically integrate contrast media intermediates.
  • Product Pipeline: The company has visibility on 4 programs in the chronic therapy space (oncology and CNS) from a tracked funnel of 20 high-conviction NCE opportunities. For FY27, 3 new candidates in Contrast Media and a new high-intensity sweetener are planned for launch/pilot.
  • Capex Guidance: Expected capital expenditure for the next three years is approximately INR 1,000 crores, with about INR 250 crores planned for FY27.
  • Sustainability: 70% of energy consumption is from renewable sources. The company has received the EcoVadis Silver Medal and the CII National Award for Excellence in Energy Management.

Additional Notes Section

The document provided is the edited transcript of the earnings call, filed pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015. The transcript was signed by Sweta Poddar, Company Secretary & Compliance Officer, on August 07, 2026.

The announcement itself did not disclose financial figures; all financial data was discussed within the enclosed transcript of the call. No attachments (e.g., invite, investor deck) were mentioned as being included with this specific filing, though the presentation and results were referenced as being available on the company website.